F. Fakhouri and V. Fremeaux-bacchi, Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?, Nat Clin Pract Nephrol, vol.3, pp.679-87, 2007.

V. Fremeaux-bacchi, F. Fakhouri, A. Garnier, F. Bienaime, M. A. Dragon-durey et al., Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults, Clin J Am Soc Nephrol, vol.8, pp.554-62, 2013.

M. Furlan, R. Robles, M. Galbusera, G. Remuzzi, P. A. Kyrle et al., von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome, N Engl J Med, vol.339, pp.1578-84, 1998.

F. Fakhouri, L. Roumenina, F. Provot, M. Sallee, S. Caillard et al., Pregnancyassociated hemolytic uremic syndrome revisited in the era of complement gene mutations, J Am Soc Nephrol, vol.21, pp.859-67, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00512540

M. Sallee, K. Ismail, F. Fakhouri, H. Vacher-coponat, J. Moussi-frances et al., Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome, BMC Nephrol, vol.14, p.3, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00780835

F. Fakhouri, J. P. Vernant, A. Veyradier, M. Wolf, G. Kaplanski et al., Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases, Blood, vol.106, pp.1932-1939, 2005.

R. Kelly, L. Arnold, S. Richards, A. Hill, C. Bomken et al., The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab, Br J Haematol, vol.149, pp.446-50, 2010.

J. Zuber, F. Fakhouri, L. T. Roumenina, C. Loirat, and V. Fremeaux-bacchi, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nat Rev Nephrol, vol.8, pp.643-57, 2012.

C. Parker, Eculizumab for paroxysmal nocturnal haemoglobinuria, Lancet, vol.373, pp.759-67, 2009.

C. Licht, P. Muus, C. M. Legendre, K. W. Douglas, M. Hourmant et al., Eculizumab (ECU) safety and efficacy in atypical hemolytic uremic syndrome (aHUS) patients with long disease duration and chronic kidney disease (CKD): 2-year results, Blood, vol.120, 2012.

L. Greenbaum, C. M. Legendre, S. Babu, R. R. Furman, N. Sheerin et al., Eculizumab (ECU) in atypical hemolytic uremic syndrome (aHUS) patients with progressing thrombotic microangiopathy (TMA): 2-year data, Blood, vol.120, 2012.

P. Coppo, D. Bengoufa, A. Veyradier, M. Wolf, A. Bussel et al., Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement, Medicine, vol.83, pp.233-277, 2004.

M. Lemaire, V. Fremeaux-bacchi, F. Schaefer, M. Choi, W. H. Tang et al., Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome, Nat Genet, vol.45, pp.531-537, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01064383